Alexandru Stieber/LinkedIn
Dec 18, 2025, 13:34
Alexandru Stieber Explores VEXAS Syndrome
Alexandru Stieber, Internal Medicine Resident at SUUMC Bucharest, shared on LinkedIn:
”Second set of scientific updates from the SNFMI Congress that took place last week in Tours, France.
The theme of today’s post revolves around VEXAS syndrome, new implications for patients with a VEXAS-like phenotype and the evolving concept of “clonal hematopoiesis of immunological significance” (CHIS).
- proven efficacy of azacitidine treatment in VEXAS patients, even in the absence of myelodysplastic syndrome
- proven pathophysiology of UBA1 mutated myeloid cells that drive an inflammatory millieu which alters normal hematopoiesis
- new links found between clonalhematopoiesis with IDH mutations and inflammatory manifestations (polymyalgia rheumatica and large-vessel vasculitis), with resolution under targeted inhibitors”

Stay updated with Hemostasis Today.
-
Aug 23, 2026, 17:51Gurpreet Kaurr: A Proud Milestone in Haematology and Oncology
-
Aug 23, 2026, 17:33Kathrine Kaspersen: How Voluntary Plasma Donors Helped Transform Denmark’s Plasma Supply
-
Aug 23, 2026, 16:51Sthanu Subramanian: Empagliflozin and a Rise in Hematocrit
-
Aug 23, 2026, 16:50Lale Tokgözoğlu: New PCSK9i Research Published in the European Heart Journal
-
Aug 23, 2026, 16:44Eric Gehrie: Your 2026 Guide to the Essentials of Transfusion Medicine
-
Aug 23, 2026, 16:35Thomas Dayspring: The Overlooked Pathway in Cholesterol Homeostasis
-
Aug 23, 2026, 16:28Evan Mapelu: The People Who Make Cancer Care Meaningful
-
Aug 23, 2026, 16:09Felice Gragnano: New Publication on Aspirin Discontinuation After PCI for Acute Coronary Syndromes
-
Aug 23, 2026, 16:06Mostafa Faisal: Donor Type and Long-Term Quality of Life After HCT for Severe Aplastic Anemia